Summary:
A large-scale analysis of more than 187,000 adults aged 50 and older enrolled in the NIH’s All of Us Research Program found that older adults with attention-deficit/hyperactivity disorder (ADHD) have a substantially increased risk of later-life cognitive impairment. Researchers at the University of Pittsburgh School of Medicine report in JAMA Psychiatry that a clinical ADHD diagnosis was associated with more than a fourfold higher risk of progressing to mild cognitive impairment (MCI) or dementia. By combining electronic health records with genomic data, the team also found that higher genetic liability for ADHD—measured by polygenic risk scores (PRS)—was linked to a 35% greater chance of developing dementia even in people without a formal ADHD diagnosis, supporting a biological connection between ADHD and cognitive decline.
Key Facts:
- Markedly increased dementia risk: After adjusting for age, sex, and medical comorbidities, a recorded ADHD diagnosis corresponded to an adjusted hazard ratio indicating more than four times the risk of progressing to MCI or dementia.
- Genetic predisposition matters: Individuals in the highest quintile of ADHD polygenic risk scores had a 35% higher incidence of dementia compared with those in the lowest quintile, even if they were never clinically diagnosed with ADHD.
- Greater burden when conditions co-occur: People with both ADHD and cognitive impairment reported worse mental health, lower life satisfaction, reduced social engagement, and used about 20% more healthcare resources in the year after their cognitive diagnosis.
Source: University of Pittsburgh
ADHD is often thought of as a childhood disorder, but mounting evidence shows it frequently persists through adulthood and can affect functioning across the lifespan. Past, smaller studies from Scandinavia and Europe suggested a possible link between adult ADHD and increased vulnerability to neurodegenerative conditions in later life. Critics raised the possibility that early dementia symptoms might be misdiagnosed as late-onset ADHD, however, leaving open whether the association reflects shared biology or diagnostic overlap.
This new investigation offers the most comprehensive evidence to date that clinical ADHD and late-life cognitive impairment share both clinical and genetic underpinnings. Using electronic health records and genomic data from 187,341 diverse participants aged 50 and older in the All of Us cohort, the research team found a strong association between ADHD and later cognitive decline and demonstrated that ADHD-related genetic variation independently predicts dementia risk.
Genomic Evidence From the All of Us Cohort
The cohort included 187,341 participants (mean age 56.4 years; 57% female) with linked longitudinal health records and genome-wide data. Overall, 1.6% of the sample (3,026 people) had an ADHD diagnosis in their records. Among those with ADHD, 6.7% later developed MCI or dementia compared with 3.4% of those without ADHD.
After adjusting for potential confounders—including age, sex, cardiovascular conditions, education, and healthcare utilization—the investigators observed that having an ADHD diagnosis was associated with a greater than fourfold increased hazard of incident cognitive impairment. To reduce the likelihood that early dementia was being misclassified as ADHD, the team applied an eight-year analytical buffer, requiring at least eight years to pass between an ADHD diagnosis and subsequent cognitive impairment; the association remained significant under this conservative approach.
To assess genetic contribution, researchers calculated ADHD polygenic risk scores that aggregate common genetic variants associated with ADHD. Participants in the highest genetic-risk quintile experienced a 35% higher hazard of developing dementia than those in the lowest quintile—even among individuals without a recorded ADHD diagnosis—strengthening the case for a biological link rather than purely diagnostic artifact.
The Compounded Clinical Burden of Dual Diagnoses
Beyond the increased incidence, the study examined outcomes for people who developed cognitive impairment. Within this subgroup, those with a comorbid ADHD diagnosis exhibited worse mental health and quality-of-life measures compared with people who had cognitive impairment alone. Specifically, comorbid ADHD was associated with higher odds of depression and internal distress, lower subjective life satisfaction and social engagement, and approximately 20% higher healthcare utilization during the year following the cognitive diagnosis—indicating greater care needs and a heavier clinical burden.
“Combining genetic data with long-term health records makes it possible to detect signals that smaller studies might miss,” said co-first author Guilherme Bauer-Negrini, Ph.D. The convergent evidence from independent clinical records and genetic analyses increases confidence that ADHD is relevant to cognitive aging and warrants closer attention in neuropsychiatric research and clinical practice.
Therapeutic Questions and Future Directions
These findings raise several important questions for future research and clinical care. Key topics include whether long-term use of stimulant medications that influence dopamine and norepinephrine systems modifies dementia risk, and whether treating modifiable cardiovascular and lifestyle factors commonly associated with ADHD—such as sleep disruption, chronic stress, smoking, and metabolic disease—could reduce late-life cognitive risk.
The authors emphasize that an ADHD diagnosis does not make dementia inevitable. Instead, the combined clinical and genetic evidence supports treating adult ADHD as a potential, modifiable risk factor that may benefit from proactive monitoring and integrated care strategies across the lifespan to support healthier cognitive aging.
Funding: Supported by the National Institute on Aging, the Alzheimer’s Association, the U.K. National Institute for Health and Care Research, and the European Research Executive Agency. Specific grant numbers are reported by the study authors.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this Neurology and Neuropharmacology Research:
- Media Contact: Liz Reid
- Source: UPMC
- Image Credit: Image credited to Neuroscience News
- Original Research: JAMA Psychiatry (Oct 7, 2026). Title: “Attention-Deficit/Hyperactivity Disorder and Late-Life Cognitive Impairment.” Authors: Guilherme Bauer-Negrini et al.
- DOI: 10.1001/jamapsychiatry.2026.3165
Abstract
Attention-Deficit/Hyperactivity Disorder and Late-Life Cognitive Impairment
Importance
ADHD affects millions of adults worldwide, and emerging evidence suggests it may be linked to higher risk of mild cognitive impairment and dementia. Persistent questions about diagnostic accuracy and confounding factors have limited causal interpretation.
Objective
To evaluate the association between ADHD and incident cognitive impairment (MCI or dementia) using electronic health record diagnoses and genome-wide ADHD polygenic risk scores in the same individuals.
Design, Setting, and Participants
Cohort study using data from the US All of Us Research Program (enrollment May 6, 2018, to October 1, 2023; EHR coverage January 4, 1985, to October 1, 2023). The study included 187,341 participants aged 50 years and older with available EHR and genomic data; mean follow-up was 10.26 years. Data were analyzed from October 2025 to July 2026.
Exposures
ADHD clinical diagnosis and ADHD polygenic risk score (PRS).
Main Outcomes and Measures
Incident mild cognitive impairment or dementia.
Results
Among 187,341 participants (mean age 56.41 years; 57% female), 3,026 (1.6%) had ADHD. Incident cognitive impairment occurred in 6.7% of those with ADHD versus 3.4% without. In adjusted Cox models, ADHD was associated with a more than fourfold higher hazard of cognitive impairment (HR, 4.60; 95% CI, 3.99–5.29; P < .001). ADHD PRS was independently associated with incident cognitive impairment (highest vs lowest quintile: HR, 1.35; 95% CI, 1.25–1.46; P < .001). Among participants who developed cognitive impairment, comorbid ADHD was linked to worse mental health, poorer quality of life and social satisfaction, and approximately 20% higher healthcare utilization, indicating greater care burden in addition to higher incidence risk.
Conclusions and Relevance
Convergent clinical and genetic evidence in this large cohort indicates ADHD is associated with substantially increased risk of late-life cognitive impairment. When cognitive impairment does occur, individuals with ADHD experience poorer outcomes and greater healthcare needs, highlighting the importance of targeted monitoring and integrated care for this population.